1x03 - The Nurses’ voice on Biosimilar medicines. An opportunity for integrated care
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
1x03 - The Nurses’ voice on Biosimilar medicines. An opportunity for integrated care
-
ナレーター：
-
著者：
このコンテンツについて
Conversations on EU Pharma is back with a third episode we will explore the role played by specialised nurses in delivering positive patient outcomes with biologic therapies and the development of integrated care for patients living with Non-Communicable Diseases (NDC), starting with an overview on the impacts of Covid-19 on the nursing community.
Joining the discuss on the benefits of Biosimilar Medicines were:
- Adriano Friganovic, President of the European Specialist Nurses Organisation - ESNO
- Hanneke Voorneveld-Nieuwenhuis, Nurse Practitioner, Maasstad hospital, The Netherlands
As the host for this episode you will find Kate O’Regan, Communications & Stakeholder Relations Senior Manager from Medicines for Europe.
If would like to know more about this topic, you can dive into the resources mentioned during this episode:
- Nurses’ Knowledge and Attitudes towards Biosimilar Medicines as Part of Evidence-Based Nursing Practice—International Pilot Study within the Project Biosimilars Nurses
- The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study
- A Communication and Information guide for nurses: Switch Management between Similar Biological Medicines
Listen to the episode on:
Amazon Music – Apple Podcast – Castbox – Google Podcasts – OverCast – Pocket Casts – RadioPublic – YouTube – Spotify – Stitcher